Vitamin D3 Streuli 300,000 IU 1 ml solution for injection ampoules
Streuli
Medicine / Vitamin supplementInjectable cholecalciferol (Vitamin D3)
Certifications
- Listed in UK dm+d database as imported product (Imported (Switzerland)) with SNOMED code 19981011000001109. :contentReference[oaicite:22]{index=22}
- ATC classification: A11CC05 – Colecalciferol (Vitamin D3) as per Swiss compendium. :contentReference[oaicite:23]{index=23}
- Marketing authorisation in Switzerland under Swissmedic registration number 32435. :contentReference[oaicite:24]{index=24}
- Listed in UK dm+d database as imported product (Imported (Switzerland)) with SNOMED code 19981011000001109. :contentReference[oaicite:22]{index=22}
- ATC classification: A11CC05 – Colecalciferol (Vitamin D3) as per Swiss compendium. :contentReference[oaicite:23]{index=23}
- Marketing authorisation in Switzerland under Swissmedic registration number 32435. :contentReference[oaicite:24]{index=24}
Injectable cholecalciferol (Vitamin D3)
Description
An injectable vitamin D3 (cholecalciferol) solution, delivering 300,000 IU per 1 ml ampoule. It is used in medical settings to treat vitamin D deficiency when oral therapy is inadequate or impractical, such as in malabsorption-associated osteomalacia, postoperative hypoparathyroidism, or hypocalcaemic tetany. Pack contains 10 ampoules × 1 ml. :contentReference[oaicite:2]{index=2}
Bnefits
- Allows rapid and effective repletion of Vitamin D3 stores when oral route is not feasible (e.g. malabsorption)
- Supports normalization of calcium/phosphate metabolism and bone mineralization
- Provides a standardized high-dose injectable option for clinical use
- Simplifies dosing in situations requiring reliable high-dose administration
Indications
- Osteomalacia in malabsorption syndromes (> 12 years) :contentReference[oaicite:3]{index=3}
- Acute postoperative hypoparathyroidism with hypocalcaemia (> 12 years) when oral therapy is not effective :contentReference[oaicite:4]{index=4}
- Hypocalcaemic tetany when oral therapy is impossible or ineffective (> 12 years) :contentReference[oaicite:5]{index=5}
Composition
- Active ingredient: Cholecalciferol (Vitamin D3) 300,000 IU per 1 ml ampoule :contentReference[oaicite:6]{index=6}
- Exipient/vehicle: Medium-chain triglycerides (Triglyzeride mittelkettige / triglycerida media) to solubilize the vitamin D3 in the injection solution :contentReference[oaicite:7]{index=7}
Formulation
- Solution for intramuscular injection (IM), 1 ml ampoule
Packaging
- 10 ampoules × 1 ml (total 10 ml) per pack — GTIN 7680324350253 :contentReference[oaicite:8]{index=8}
Usage
- Administer by intramuscular injection (IM), do not use intravenously. :contentReference[oaicite:9]{index=9}
- For acute hypoparathyroidism or hypocalcaemic tetany: give 1 ml IM (300,000 IU) initially along with IV calcium; follow-up therapy preferably with oral vitamin D3 preparations. :contentReference[oaicite:10]{index=10}
- For osteomalacia in malabsorption syndromes: 1 ml IM every 6–12 months. :contentReference[oaicite:11]{index=11}
- Ensure adequate calcium intake during and after therapy. :contentReference[oaicite:12]{index=12}
Contraindications
- Intravenous administration (only intramuscular use permitted) :contentReference[oaicite:14]{index=14}
- Hypercalcaemia, hypercalciuria, hypervitaminosis D :contentReference[oaicite:15]{index=15}
- Simultaneous use of other vitamin D analogues :contentReference[oaicite:16]{index=16}
- Infants and small children with hypothyroidism (for IM use) :contentReference[oaicite:17]{index=17}
- Pregnancy and breastfeeding (per product label) :contentReference[oaicite:18]{index=18}
- Conditions with risk of hypercalcaemia: immobilization after orthopaedic surgery, sarcoidosis (Morbus Boeck), acute pulmonary tuberculosis, history of kidney stones or renal impairment — caution advised. :contentReference[oaicite:19]{index=19}
Adverse Effects
Not publicly listed
Storage Conditions
- Store in original packaging at 15–25 °C, protected from light; do not freeze. :contentReference[oaicite:21]{index=21}
Duration
Single IM dose for acute hypoparathyroidism or tetany; for osteomalacia due to malabsorption, repeat IM every 6\u201312 months as needed. :contentReference[oaicite:13]{index=13}
Onset
Not publicly listed \u2014 onset depends on restoration of vitamin D levels and calcium/phosphate metabolism over days to weeks; no specific onset-time stated in public product literature.
